**Core Concept**
Natalizumab is a monoclonal antibody that targets the alpha-4 subunit of integrins, specifically inhibiting the interaction between alpha-4 and beta-1 or beta-7 integrins, thereby preventing the adhesion and migration of leukocytes across the blood-brain barrier. This mechanism is crucial for treating multiple sclerosis (MS) and certain other inflammatory conditions.

**Why the Correct Answer is Right**
Natalizumab's primary indication is for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and secondary progressive MS (SPMS). By inhibiting the entry of autoreactive T cells into the central nervous system (CNS), natalizumab reduces the frequency of relapses and slows disease progression. The medication also has off-label use in treating Crohn's disease, a type of inflammatory bowel disease (IBD).

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because natalizumab is not primarily used for treating rheumatoid arthritis (RA), although it does have some efficacy in treating inflammatory conditions.
**Option B:** Natalizumab is not a first-line treatment for ulcerative colitis (UC), which is another type of IBD, and its use in UC is generally limited due to an increased risk of progressive multifocal leukoencephalopathy (PML).
**Option C:** Natalizumab is not used for treating type 1 diabetes mellitus (T1DM), which is an autoimmune condition resulting from T cell-mediated destruction of pancreatic beta cells.

**Clinical Pearl / High-Yield Fact**
Natalizumab is a high-risk medication for causing PML, a rare but often fatal brain infection caused by the JC virus. Before initiating treatment with natalizumab, it is essential to assess patients for previous exposure to the JC virus and to monitor them regularly for signs of PML.

**Correct Answer: B. Crohn's disease**